Catalyzes the NADP(+)-dependent oxidative decarboxylation of isocitrate (D-threo-isocitrate) to 2-ketoglutarate (2-oxoglutarate), which is required by other enzymes such as the phytanoyl-CoA dioxygenase (PubMed:10521434, PubMed:19935646). Plays a critical role in the generation of NADPH, an important cofactor in many biosynthesis pathways (PubMed:10521434). May act as a corneal epithelial crystallin and may be involved in maintaining corneal epithelial transparency (By similarity)
Homodimer
Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes.
| Cancer Type | Mutation Percentage |
|---|---|
| Central Nervous System Astrocytoma Grade Iv | 8.16% |
| Lung Adenocarcinoma | 1.05% |
| Lung Small Cell Carcinoma | 0.30% |
| Lung Squamous Cell Carcinoma | 0.68% |
| Oesophagus Squamous Cell Carcinoma | 0.23% |
Genes with an experimentally identified or computationally predicted synthetic-lethal relationship to IDH1, aggregated across our SSL data sources. Click any partner node to view that gene’s page.
Nodes and edges are coloured by the SSL data source. Partners appearing in more than one source are shown in grey.
Total Trials Found: 53
| NCT ID | Condition | Brief Title | Phase | Status |
|---|---|---|---|---|
| NCT06445959 | Mutant IDH1 Inhibitor Olutasidenib | Phase 1b/2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor Olutasidenib | PHASE1, PHASE2 | RECRUITING |
| NCT06666712 | Brain Tumor, Recurrent, Malignant Glioma (WHO Grade III or IV), IDH1/IDH2 Mutation | Chronic CED of TPT for Recurrent Malignant Glioma | PHASE1 | RECRUITING |
| NCT06478212 | IDH1-mutant Glioma, IDH2-mutant Glioma | Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma | PHASE1, PHASE2 | ACTIVE_NOT_RECRUITING |
| NCT05588141 | Brain Tumor, Cancer | A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations | PHASE1, PHASE2 | RECRUITING |
| NCT03499912 | Acute Myeloid Leukemia | Screening of IDH1 and IDH2 Gene Mutations in Adult Acute Myeloid Leukemia for Possible Targeted Therapy | N/A | UNKNOWN |
| NCT03212274 | Advanced Malignant Solid Neoplasm, Glioblastoma, Recurrent Cholangiocarcinoma, Recurrent Glioma, Recurrent Malignant Solid Neoplasm, WHO Grade 2 Glioma, WHO Grade 3 Glioma | Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations | PHASE2 | ACTIVE_NOT_RECRUITING |
| NCT04044209 | Myelodysplastic Syndromes, Acute Myeloid Leukemia | A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS | PHASE2 | WITHDRAWN |
| NCT02597335 | Glioma, IDH1/IDH2 Mutation | Non Invasive Detection of IDH1/2 Mutation in Gliomas | NA | UNKNOWN |
| NCT06501625 | Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation | Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation | PHASE1, PHASE2 | RECRUITING |
| NCT02171286 | Colorectal Cancer Metastatic, Advanced Non-Small Cell Lung Carcinoma, Advanced Melanoma, Gastrointestinal Stromal Tumors, Patients With Diagnosed Malignancies Being Considered for Clinical Trials | The Oncopanel Pilot (TOP) Study | N/A | COMPLETED |